BioWorld Asia

Jan. 7, 2009

Genmab Shares Slide on Interim Zalutumumab Data

Shares in Genmab A/S were off by more than 7 percent during trading Tuesday following an interim update on a Phase III pivotal study of zalutumumab (HuMax-EGFr) in head and neck cancer. (BioWorld International) Read More

UK/U.S. Program Mapping Chemo Response to Cancers

Hair Loss Gene has Serendipitous Message for Genetic Sleuths

UK's Stem Cell Proponents Meeting to Discuss Future

Small EU Biofirms Benefit from Special Assistance

Cytos Shares Surge on Pfizer Deal Commitment

Cellectis Terminates genOway's Homologous Recombination Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...